Sales expenses

Recent Articles

RELATED ARTICLES

  1. The innovative drug maker’s product revenue rose 82% to $747 million in the first quarter, with its star drug on pace to possibly net $2 billion for the year.
    BeiGene’s aggressive expansion brings revenue jolt
    BGNE.US 6160.HK 688235.SHG
  2. BeiGene still bleeding red ink despite blockbuster drug
    BGNE.US 6160.HK 688235.SHG
  3. Novel drugs lift Sino Biopharm earnings, easing price-cap pain
    1177.HK
  4. Hutchmed scores U.S. success with cancer drug, but profits still dip
    HCM.US 0013.HK
  5. Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
    1952.HK
  6. CSPC Pharma taps R&D superstar in quest for new breakout drugs
    1093.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva